TNF-alpha polymorphisms as a potential modifier gene in the cystic fibrosis

International Journal of Molecular Epidemiology and Genetics

Volumn 5, Issue 2, 2014, Pages 87-99

  Coutinho, Cyntia A A C ^a   Marson, Fernando A L ^a   Marcelino, Aline R B ^a   Bonadia, Luciana C ^a   Carlin, Marcelo P ^a   Ribeiro, Antonio F ^a   Ribeiro, Jose D ^a   Bertuzzo, Carmen S ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

CFTR; Cystic fibrosis; Genotype; Inflammation; Lung disease; Modifier gene; Phenotype; Polymorphism; TNF alpha; TNF

Indexed keywords

GENOMIC DNA; HEMOGLOBIN;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE; FEMALE; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPOXEMIA; INFANT; LUNG DISEASE; MALE; MECONIUM ILEUS; MODIFIER GENE; OXYGEN SATURATION; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SPIROMETRY; TUMOR NECROSIS FACTOR ALPHA GENE;

EID: 84901798488     PISSN: 19481756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Knowles MR, Drumm M. The influence of genetics on cystic fibrosis phenotypes. Cold Spring Harb Perspect Med 2012; 2: a009548.
2. Dorfman R. Modifer gene studies to identify new therapeutic targets in cystic fibrosis. Curr Pharm Des 2012; 18: 674-682.
3. Drumm ML, Ziady AG, Davis PB. Genetic variation and clinical heterogeneity in cystic fibrosis. Annu Rev Pathol 2012; 7: 267-282.
4. Faria EJ, Faria IC, Ribeiro JD, Ribeiro AF, Hessel G, Bertuzzo CS. Association of MBL2, TGF-be-ta1 and CD14 gene polymorphisms with lung disease severity in cystic fibrosis. J Bras Pneumol 2009; 35: 334-342.
5. Lima CS, Ortega MM, Marson FA, Zulli R, Ri-beiro AF, Bertuzzo CS. Cystic fibrosis transmembrane conductance regulator gene mutations and glutathione S-transferase null genotypes in cystic fibrosis patients in Brazil. J Bras Pneumol 2012; 38: 50-56.
6. Marson FAL, Bertuzzo CS, Secolin R, Ribeiro AF, Ribeiro JD. Genetic interaction of GSH metabolic pathway genes in cystic fibrosis. BMC Med Genet 2013; 10: 60.
7. Marson FA, Bertuzzo CS, Hortencio TD, Ribeiro JD, Bonadia LC, Ribeiro AF. The ACE gene D/I polymorphism as a modulator of severity of cystic fibrosis. BMC Pulm Med 2012; 12: 41.
8. Marson FA, Bertuzzo CS, Ribeiro AF, Ribeiro JD. Polymorphisms in ADRB2 gene can modulate the response to bronchodilators and the severity of cystic fibrosis. BMC Pulm Med 2012; 12: 50.
9. Furgeri DT, Marson FA, Ribeiro AF, Bertuzzo CS. Association between the IVS4G>T mutation in the TCF7L2 gene and susceptibility to diabetes in cystic fibrosis patients. BMC Res Notes 2012; 5: 561.
10. Marson FAL, Marcelino ARB, Ribeiro AF, Ribeiro JD, Bertuzzo CS. COX-2 Gene Polymorphisms: Genetic Determinants of Cystic Fibrosis Co-morbidities. International Journal of Genetics 2013; 5: 132-138.
11. Marson FAL, Rezende LM, Furgeri DT, Ribeiro AF, Ribeiro JD, Bertuzzo CS. ADRA2A is a Cystic Fibrosis Modifer Gene. International Journal of Genetics 2013; 5: 125-131.
12. Marson FAL, Marcelino ARB, Rezende LM. The IFRD1 (57460C>T polymorphism) gene: a negative report in cystic fibrosis clinical severity. J Mol Genet Med 2013; 7: 058.
13. Wilson AG, Vries N, Poicot F, Giovine FS, Van der Putte LBA, Duff GW. An allelic polymorphism within the human tumor necrosis factor promoter region is strongly associated with the HLA al, 68, and DR3 alleles. J Exp Med 1993; 177: 557-560.
14. Huang SL, Su CH, Chang SC Tumor necrosis factor α gene polymorphism in chronic bronchitis. Am J Resp Crit Care Med 1997; 156: 1436-1439.
15. Hull J, Thompson AH. Contribution of genetics factor other than CFTR to disease severity in Cystic Fibrosis. Thorax 1998; 53: 1018-1021.
16. Yarden J, Radojkovic D, De Boeck K, Macek M Jr, Zemkova D, Vavrova V, Vlietinck R, Cassi-man JJ, Cuppens H. Association of tumor necrosis factor alpha variants with the CF pulmonary phenotype. Thorax 2005; 60: 320-325.
17. Karpati F, Hjelte FL, Wretlind B. TNF-alpha and IL-8 in consecutive sputum samples from cystic fibrosis patients during antibiotic treatment. Scand J Infect Dis 2000; 32: 75-79.
18. Pociot F, D'Alfonso S, Compasso S, Scorza R, Richiard PM. Functional analysis of a new polymorphism in the human TNFa gene promoter. Scand J Imunol 1995; 42: 501-504.
19. Huizinga TW, Westendorp RG, Bollen EL, Keijs-ers V, Brinkman BM, Langermans JA, Breed-veld FC, Verweij CL, van de Gaer L, Dams L, Crusius JB, García-Gonzalez A, van Oosten BW, Polman CH, Peña AS. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol 1997; 72: 149-153.
20. Buranawuti K, Boyle MP, Cheng S, Steiner LL, McDougal K, Fallin MD, Merlo C, Zeitlin PL, Rosenstein BJ, Mogayzel PJ Jr, Wang X, Cutting GR. Variations in mannose-binding lectin and tumor necrosis factor α affect survival in Cystic Fibrosis. J Med Genet 2007; 44: 209-214.
21. Higham MA, Pride NB, Alikhan A, Morrel NW. Tumor necrosis factor α gene promoter polymorphisms in chronic obstructive pulmonary disease. Eur Resp J 2000; 15: 281-284.
22. Sakao S, Tatsumi K, Igari H, Shino Y, Shirasawa H, Kuriyama T. Association of tumor necrosis factor α gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2001; 163: 420-422.
23. Acton JD, Wilmott RW. Phenotype of CF and the effects of possible modifer genes. Paed Resp Reviews 2001; 2: 332-339.
24. Slieker MG, Sanders EAM, Rijkers GT, Ruven HJT. Disease modifying genes in Cystic Fibro-sis. J Cyst Fibros 2005; 4: 7-13.
25. Abba AK, Lichtman AH, Pober JS. Imunologia: celular e molecular. Revinter, 1995.
26. Buscher R, Grasemann H. Disease modifying genes in Cystic Fibrosis: therapeutic option or one-way road? Naunyn-Schmiedeberg's Arch Pharmacol 2006; 374: 65-77.
27. Santos CIS, Ribeiro JD, Ribeiro AF, Hessel G. Critical analysis of scoring systems used in the assessment of cystic fibrosis severity: state of the art. J Bras Pneumol 2004; 30: 286-298.
28. Collins CE, Macdonald-Wicks L, Rowe S, O'Loughlin EV, Henry RL. Normal growth in cystic fibrosis associated with specialised center. Arch Dis Child 1999; 81: 241-246.
29. Santana MA, Matos E, Fontoura MS, Franco R, Barreto D, Lemos ACM. Prevalence of pathogens in Cystic Fibrosis patients in Bahia, Brazil. The Braz J Ofec Dis 2003; 7: 69-72.
30. Streit C, Bulamarque-Neto AC, Abreu e Silva F, Giugliani R, Pereira MLS. CFTR gene: molecular analysis in patients from south Brazil. Mol Genet Metab 2003; 78: 259-264.
31. Marostica PJ, Raskin S, Abreue-Silva FA. Analysis of delta f508 mutation in Brazilian cystic fibrosis population: comparison of pulmonary status of homozygotes with other patients. Braz J Med Biol Res 1998: 31: 529-532.
32. Dorfman R, Sandford A, Taylor C, Huang B, Frangolias D, Wang Y, Sang R, Pereira L, Sun L, Berthiaume Y, Tsui LC, Paré PD, Durie P, Corey M, Zielenski J. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest 2008; 118: 1040-1049.
33. Schmitt-Grohé S, Stüber F, Book M, Bargon J, Wagner TO, Naujoks C, Schubert R, Lentze MJ, Zielen S. TNF-alpha promoter polymorphism in relation to TNF-alpha production and clinical status in Cystic Fibrosis. Lung 2006; 184: 99-104.
34. Arkwright PD, Pravica V, Geraghty PJ, Super M, Webb AK, Schwarz M. End-organ dysfunction in cystic fibrosis. Am J Crit Care Med 2003; 167: 384-389.